Skip to content

A multicenter double-blind, randomized controlled study of air-bag type sequential external counter-pulsation in the treatment of cognitive impairment after stroke

A multicenter double-blind, randomized controlled study of air-bag type sequential external counter-pulsation in the treatment of cognitive impairment after stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099707
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Conventional standard treatment combined with air-bag type sequential external counter-pulsation group:Air-bag type sequential external counter-pulsation + conventional standard treatment (i.e., stand
Conventional standard treatment :Sham extracorporeal balloon counterpulsation + conventional standard of care

Sponsors

The Seventh Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. First non-cardiogenic ischemic stroke (meeting the diagnostic criteria of the 2018 Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke), and the onset time is within 4 days to 3 weeks, male or female; 2.Between the ages of 18 and 80; 3.Obtaining informed consent.

Exclusion criteria

Exclusion criteria: 1.Significant cognitive, language, mental and behavioral abnormalities that cannot cooperate with testing and follow-up; 2.Participated in other clinical trials within 3 months; 3.Patients who have taken any autonomic nervous system medications such as catecholamine depleting agents, ß-blockers, a-blockers, antipsychotics, monoamine oxidase inhibitors, and tricyclic antidepressants within 14 days prior to enrollment; 4.Accompanied by neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, mitochondrial encephalomyopathy, motor neuron disease, etc.); 5.Patients with severe organ dysfunction: alanine aminotransferase> 3 times the upper limit of normal; aspartate aminotransferase > 5 times the upper limit of normal; eGFR, 180 mm Hg or diastolic blood pressure >100 mm Hg); 10.Patients with epilepsy, pregnancy, metal or electronic implants in the body, obvious mental disorders, cognitive disorders, and claustrophobia that cannot cooperate with MRI examination.

Design outcomes

Primary

MeasureTime frame
Cognitive function;Gait function;

Secondary

MeasureTime frame
Post-stroke autonomic dysfunction;Covert cerebrospinal fluid circulation disorders;

Countries

China

Contacts

Public ContactQinghua Hou

The Seventh Affiliated Hospital of Sun Yat-sen University

houqinghua@sysush.com+86 180 2628 0279

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026